HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors

Summary

This Phase1, open-label and dose-escalation study will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy of HLX07 administered as a single-agent by IV infusion every 3 weeks to patients with locally advanced or metastatic solid malignancies, who have failed or are intolerant to standard therapy, or for whom no standard therapy is available.

Timeline

Start

2023-03-30

Primary completion

2023-12-30

Completion

2024-02-28

Drugs

Indications